From Wikipedia, the free encyclopedia - View original article
Daytrana (formerly known as MethylPatch) is a medicinal patch marketed and developed under contract by Noven Pharmaceuticals that was approved in April 2006. In the literature, Daytrana is most commonly referred to as Methylphenidate Transdermal System (MTS).
Daytrana is approved by the U.S. Food and Drug Administration (FDA) as a once daily treatment of pediatric and adolescent patients—ages 6 to 17—with Attention Deficit Hyperactivity Disorder. However, off-label prescriptions in older patients are not uncommon. It is mainly prescribed as a second-line treatment for ADHD when traditional oral forms are not well-tolerated or if patients have difficulty with compliance.
Noven's original FDA submission of MethylPatch indicated that it should be used for 12 hours; when the FDA rejected the submission they requested evidence that a shorter time period was safe and effective; Noven provided such evidence and Daytrana was approved for the aforementioned indication over a 9 hour period.
Unlike with transdermal administration, orally administered methylphenidate is subject to first-pass metabolism, by which the levo-isomer is extensively metabolized. By circumvention of this first-pass metabolism the relative concentrations of l-threo-methylphenidate are much higher with transdermal administration (50-60 % of those of dexmethylphenidate instead of about 14-27 %).   Because the d-enantiomer by far is pharmacologically the most active one, this is of limited importance.
|This medical treatment–related article is a stub. You can help Wikipedia by expanding it.|